<!DOCTYPE html>
<html>
    <head>
        <title>STD Tx Guidelines</title>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g12" data-theme="a">
            <div data-role="header" data-id="guidelines-header" data-theme="b" data-position="fixed">
                <a href="lv-6.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h3>STD Tx Guidelines</h3>
                <a href="#nav-panel" class="ui-btn ui-icon-bars ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-4.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-4.html" >Clinical Prevention Guidance</a><span class="carrot"> > </span>
                    <a href="lv-6.html" >Prevention Methods</a><span class="carrot"> > </span>Topical Microbicides and Spermicides
            </div>
            </br><h3 class="sgc-1" id="sigil_toc_id_12">
 Topical Microbicides and Spermicides
</h3>
<p>
 Studies examining nonspecific topical microbicides for the prevention of HIV and STD have demonstrated that these products are ineffective (38,39). Studies of spermicides containing N-9 have demonstrated that they should not be recommended for STDs/HIV prevention (40), and more recent randomized controlled trials have failed to show a protective effect against HIV acquisition for BufferGel (a vaginal buffering agent), Carraguard (a carrageenan derivative) (41), cellulose sulfate (an HIV entry inhibitor), (42) and SAVVY (1.0% C31G, a surfactant) (43,44).
</p>
<p>
 Initial results from a study in which participants used 0.5% PRO2000 vaginal gel (a synthetic polyanion polymer that blocks cellular entry of HIV) on a daily basis appeared promising, reducing the rate of HIV acquisition by 30% relative to no gel (45). However, a recent randomized trial of approximately 9,000 women failed to show any protective effect (46).
</p>
<p>
 Topical antiretroviral agents for the prevention of HIV appear more promising. Use of tenofovir gel during sexual intercourse significantly reduced the rate of HIV acquisition (i.e., by 39%) in a study of South African women (47). Additional studies are being undertaken to elucidate the optimal dosing regimens for this drug.
</p>
<p>
 Other products remain under study, including VivaGel, a topical vaginal microbicide. A list of products under development is maintained by the Alliance for Microbicide Development at
 <a href="http://www.microbicide.org" onclick="openLink('http://www.microbicide.org');" rel="external" target="_blank">
  www.microbicide.org
 </a>
 .
</p>

            </div>
        <div data-role="panel" data-display="push" data-theme="b" id="nav-panel">
            <ul data-role="listview">
                <li data-icon="delete"><a href="#" data-rel="close">Close menu</a></li>
                <li><a href="../conditions/c0-clv.html">Condition Quick Pick</a></li>
                <li><a href="../guidelines/lv-0.html">Full STD Tx Guidelines</a></li>
                <li><a href="../page/hx-pdf.html">Taking a Sexual Hx PDF</a></li>
                <li><a href="../terms/1.html">Terms and Abbreviations</a></li>
                <li><a href="../refs/lv-0.html">References</a></li>
                <li><a href="../page/about_us.html">About Us</a></li>
            </ul>
        </div><!-- /panel -->
    
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>
    